EPO906 in Carcinoid and Other Neuroendocrine Tumors
NCT00050349
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
33
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoid
Neuroendocrine Tumors
Interventions
DRUG:
EPO906 epothilone B
Sponsor
Novartis Pharmaceuticals